In the Netherlands, the majority of insulins for T2DM are prescribed in primary care.7 The guideline of the Dutch College of General Practitioners NHG-Standaard diabetes mellitus type 2 advises against the use of the newer insulins, for reasons of non-evidence-based advantages compared with other intermediate and long-acting insulins.5 In addition, insulin degludec has an unknown long-term safety and is more expensive than other insulins. Here, INS is linked to type 2 diabetes mellitus.